Part 2 in our Fall 2024 Inflation Reduction Act (IRA) Webinar Series
There have already been significant impacts of the Inflation Reduction Act (IRA) on the pharmaceutical and biotech industries, and its subsequent effect on innovation and patient access to treatments. The new regulations introduced by the IRA have already begun to reshape how companies within these sectors decide on investments, potentially leading to a reduced availability of treatments for complex diseases and disorders.
During this webinar, we will explore and discuss:
- Insights from patient advocacy groups regarding the IRA’s impact on treatment advancements
- Shifts in drug development priorities within biotech firms and their discussions with investors
- Projected effects of the IRA on innovation, particularly for specific patient populations
Join us as we bring together perspectives from patient advocacy groups and biotech professionals to discuss the emerging concerns and explore actionable strategies to mitigate potential access limitations for patients.
Moderator:
- Martin Strebl-Bantillo, Principal, Strategy Consulting, Lumanity
Panelists:
- Candace Dematteis, Policy Director, Partnership to Fight Chronic Disease
- Catherine Sabatos-Peyton, CEO, Larkspur Biosciences
November 12, 2024 I 10:30am – 11:30am ET